Dermata, the ingredient supplier known for developing advanced skincare compounds, is moving into the consumer market with Tome, a weekly treatment that positions itself as an accessible alternative to professional microneedling.
The brand's flagship product costs $45 and uses spicules—tiny, naturally derived particles—to create controlled micro-injuries on the skin's surface. Unlike traditional microneedling needles, spicules work through friction rather than puncture, offering gentler exfoliation with the same collagen-stimulating benefits. The treatment is designed for once-weekly use, making it a maintenance routine rather than an intensive procedure.
Dermata's pivot from B2B ingredient development to direct-to-consumer reflects growing consumer appetite for clinical-grade skincare they can use at home. The category has exploded in recent years, with brands like Olaplex and The Ordinary building billion-dollar valuations on accessible formulations and affordable price points.
Tome's positioning as "microneedling lite" targets a specific gap in the market. Professional microneedling requires dermatologist visits, costs significantly more per session, and carries downtime risks. At-home microneedling devices exist but carry safety concerns and varying efficacy levels. Spicule treatments occupy middle ground—more dramatic than standard exfoliants, less invasive than needling, and designed for routine use without professional supervision.
The move represents a broader industry shift. Ingredient companies increasingly recognize that controlling the consumer experience—not just the formula—drives brand loyalty and premium pricing. By launching Tome, Dermata captures margin at retail rather than wholesale and builds direct relationships with end users.
Success depends on demonstrating real results at the weekly cadence and price point. Consumers spending $45 weekly will demand visible skin improvements within weeks, not months. The spicule delivery system must prove both effective and